Clinical Trial Update: A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

This document reports an early-phase (Phase Ib) trial of QLS4131 for systemic lupus erythematosus. The study is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• QLS4131

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: NOT_YET_RECRUITING